Relay Therapeutics, Inc.

NasdaqGM:RLAY 株式レポート

時価総額：US$921.2m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Relay Therapeutics マネジメント

マネジメント 基準チェック /24

Relay Therapeutics'の CEO はSanjiv Patelで、 Mar2017年に任命され、 の在任期間は 7.25年です。 の年間総報酬は$ 19.77Mで、 3.4%給与と96.6%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.03%を直接所有しており、その価値は$ 9.97M 。経営陣と取締役会の平均在任期間はそれぞれ6.2年と4.8年です。

主要情報

Sanjiv Patel

最高経営責任者

US$19.8m

報酬総額

CEO給与比率3.4%
CEO在任期間7.3yrs
CEOの所有権1.0%
経営陣の平均在職期間6.2yrs
取締役会の平均在任期間4.8yrs

経営陣の近況

Recent updates

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Apr 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Just Trimmed Their Revenue Forecasts By 12%

Relay Therapeutics: Platform More Important Than Programs

Mar 13

Relay Therapeutics: Tapping Into An Unmet Need At A High Price Tag

Feb 13

Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 21
Analyst Forecasts Just Became More Bearish On Relay Therapeutics, Inc. (NASDAQ:RLAY)

We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Nov 14
We Think Relay Therapeutics (NASDAQ:RLAY) Can Afford To Drive Business Growth

Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Jun 08
Will Relay Therapeutics (NASDAQ:RLAY) Spend Its Cash Wisely?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Feb 22
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Oct 23
Is Relay Therapeutics (NASDAQ:RLAY) In A Good Position To Invest In Growth?

Relay set to Equal Weight at Barclays; says fairly valued ahead of catalysts

Sep 30

Relay Therapeutics: Bile Duct Cancer Approval Shot Validates Pricey Platform

Sep 18

Why did Relay Therapeutics stock drop today?

Sep 09

Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Jan 02
Estimating The Fair Value Of Relay Therapeutics, Inc. (NASDAQ:RLAY)

Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Aug 17
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Reducing Their Forecasts For This Year

Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 16
Relay Therapeutics, Inc. (NASDAQ:RLAY) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Mar 26
Relay Therapeutics (NASDAQ:RLAY) Is In A Strong Position To Grow Its Business

Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares

Feb 01
Read This Before Selling Relay Therapeutics, Inc. (NASDAQ:RLAY) Shares

CEO報酬分析

Relay Therapeutics の収益と比較して、Sanjiv Patel の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$329m

Dec 31 2023US$20mUS$674k

-US$342m

Sep 30 2023n/an/a

-US$326m

Jun 30 2023n/an/a

-US$344m

Mar 31 2023n/an/a

-US$323m

Dec 31 2022US$8mUS$642k

-US$291m

Sep 30 2022n/an/a

-US$290m

Jun 30 2022n/an/a

-US$267m

Mar 31 2022n/an/a

-US$384m

Dec 31 2021US$9mUS$603k

-US$364m

Sep 30 2021n/an/a

-US$261m

Jun 30 2021n/an/a

-US$414m

Mar 31 2021n/an/a

-US$247m

Dec 31 2020US$4mUS$585k

-US$230m

Sep 30 2020n/an/a

-US$289m

Jun 30 2020n/an/a

-US$95m

Mar 31 2020n/an/a

-US$86m

Dec 31 2019US$4mUS$585k

-US$75m

報酬と市場: Sanjivの 総報酬 ($USD 19.77M ) は、 US市場 ($USD 3.37M ) の同規模の企業の平均を上回っています。

報酬と収益: Sanjivの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Sanjiv Patel (50 yo)

7.3yrs

在職期間

US$19,770,838

報酬

Dr. Sanjiv K. Patel, M.A., M.D., M.B.A., MBBS, had been an Independent Director at Prothena Corporation plc since May 18, 2021 until July 1, 2023. He serves as Independent Director of ARYA Sciences Acquisi...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Alexis Borisy
Co-Founder & Independent Chairman9.2yrsUS$581.14k0.18%
$ 1.6m
Sanjiv Patel
CEO, President & Director7.3yrsUS$19.77m1.03%
$ 9.5m
Mark Murcko
Co-Founder & Directorno dataUS$548.64k0.75%
$ 6.9m
Thomas Catinazzo
Chief Financial Officer6.2yrsUS$5.22m0.026%
$ 235.1k
Brian Adams
Chief Legal Officer & Secretary6.3yrsUS$4.51m0.026%
$ 239.1k
Peter Rahmer
Chief Corporate Development Officerno dataUS$6.78m0.036%
$ 333.0k
Donald Bergstrom
President of Research & Development6.2yrsUS$8.57m0.041%
$ 381.2k
Jim Watters
Chief Scientific Officer of Late Researchno dataデータなしデータなし
Beni Wolf
Chief Medical Officer & Head of Precision Medicine4.6yrsデータなしデータなし
Mahesh Padval
Chief Pharmaceutical Development Officer5.5yrsデータなしデータなし
Pascal Fortin
Chief Scientific Officer of Early Researchno dataデータなしデータなし
Pat Walters
Chief Data Officerno dataデータなしデータなし

6.2yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: RLAYの経営陣は経験豊富で経験豊富です（平均在職期間は6.2年）。

取締役

名称ポジション在職期間報酬所有権
Alexis Borisy
Co-Founder & Independent Chairman9.2yrsUS$581.14k0.18%
$ 1.6m
Sanjiv Patel
CEO, President & Director7.3yrsUS$19.77m1.03%
$ 9.5m
Mark Murcko
Co-Founder & Director7.9yrsUS$548.64k0.75%
$ 6.9m
Douglas Ingram
Independent Director5yrsUS$548.64k0.019%
$ 173.5k
Linda Hill
Independent Director5.7yrsUS$551.14k0%
$ 0
George Demetri
Member of Oncology Advisory Board4.3yrsデータなしデータなし
Laura Shawver
Independent Director7.3yrsUS$551.14k0.030%
$ 277.6k
Lillian Siu
Member of Oncology Advisory Board4.3yrsデータなしデータなし
Jamilu Rubin
Independent Director4.7yrsUS$558.64k0.051%
$ 466.7k
Pamela Munster
Member of Oncology Advisory Board4.3yrsデータなしデータなし
Trever Bivona
Member of Oncology Advisory Board4.3yrsデータなしデータなし
Dejan Juric
Member of Oncology Advisory Board4.3yrsデータなしデータなし

4.8yrs

平均在職期間

62.5yo

平均年齢

経験豊富なボード: RLAYの 取締役会 は 経験豊富 であると考えられます ( 4.8年の平均在任期間)。